Tag: nasdaq:srpt

August 20, 2019

Sarepta Therapeutics Receives FDA Rejection, Shares Dip

The company's share price dropped by more than 20 percent after the decision from the regulatory agency on Monday.
August 8, 2019

Sarepta Dips on “Erroneous” Report to FDA

The company's share price dropped as much as 10 percent in midday trading on Thursday. It closed at US$132.98.
July 2, 2019

5 Top Biotechnology ETFs

For investors looking for less volatility compared to stocks, here's an overview of the five largest biotechnology ETFs for consideration.
January 17, 2019

How Will the FDA Shutdown Affect the Biotech Industry?

No information has been released on how the FDA will manage the possible influx of drug applications once the shutdown...
January 2, 2019

Sarepta Therapeutics Partners with Aldervron

The new partnership is set to be long-term and strategic for the plasmid DNA for Sarepta’s pipeline programs.
January 2, 2019

Sarepta Therapeutics Enters into Long-term Strategic Relationship with Aldevron

Sarepta Therapeutics (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases and Aldevron, the leading producer of custom nucleic...
December 20, 2018

Sarepta Therapeutics Completes Submission of New Drug Application Seeking Approval of Golodirsen (SRP-4053)

Sarepta Therapeutics (NASDAQ:SRPT), a leader in precision genetic medicine for rare diseases, announced today that it has completed the submission...